HealthcareOn the MoveCelgene (NASDAQ:CELG) drops 1.8% AH after stating it will discontinue Phase III trials for...Nov. 22, 2011 5:06 PM ETCelgene Corporation (CELG) StockCELGBy: Eric Jhonsa, SA News Editor Celgene (NASDAQ:CELG) drops 1.8% AH after stating it will discontinue Phase III trials for evaluating the use of its Revlimid drug to help treat prostate cancer. Recommended For YouMore Trending NewsSee More »Related StocksSymbolLast Price% ChgCELG--Celgene CorporationTrending AnalysisTrending News